PCSK9 and angina pectoris: The meta-analysis implied that against the statin group, the PCSK9 inhibitor plus statin group reduced MACE incidence by 39% (RR: 0.61; 95% CI: 0.50–0.75; p < 0.001; Figure 4A), NFMI incidence by 40% (RR: 0.60; 95% CI: 0.42–0.86; p = 0.005; Figure 4B), and rates of rehospitalization for unstable angina by 50% (RR: 0.50; 95% CI: 0.29–0.85; p = 0.011; Figure 4D).